Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK, Avalon Launch Two New Companies
by Michael McCoy
September 29, 2014
| A version of this story appeared in
Volume 92, Issue 39
GlaxoSmithKline and the venture capital firm Avalon Ventures have formed their second and third companies as part of a collaboration that began in 2013 to jointly invest up to $495 million in 10 new firms. Sitari Pharmaceuticals was formed last November to target celiac disease. The partners now have created Silarus Therapeutics, which is targeting iron disorders using intellectual property from UCLA, and Thyritope Biosciences, a thyroid disease firm based on technology from UC Santa Barbara. Both will receive up to $10 million in funding plus R&D support.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter